Global Point of Care
When time matters
The ID NOW™ molecular respiratory testing platform delivers fast, reliable results, so you can make clinical decisions during the first patient examination.
For In Vitro Diagnostic Use Only
For In Vitro Diagnostic Use Only
When time matters
The ID NOW™ molecular respiratory testing platform delivers fast, reliable results, so you can make clinical decisions during the first patient examination.
increased impact
Is within Reach
The ID Now Difference
Accurate, actionable results during the first patient visit
ID NOW™ is the only point-of-care molecular testing platform to provide actionable results in 13 minutes or less—and positive results within 6 minutes—for SARS-COV-2, Influenza A & B, RSV, and Strep A . With accuracy equivalent to RT-PCR and superior to rapid antigen-based tests, ID NOW™ enables you to initiate treatment and targeted infection control measures sooner—during the initial patient encounter.*
The point-of-care platform that improves your processes
ID NOW™ is specifically designed to meet the needs of acute care personnel, decreasing turnaround times and integrating seamlessly into acute care settings and workflows. ID NOW™ can help you save time, increase efficiencies, and maximise care quality at the beginning of the patient journey.
Watch the video to explore how id now™ can optimise your respiratory testing pathway at the point of care.
Watch Dr. Yusuf Gray, Advanced Biomedical Scientist, discuss his experience with ID NOW™ in the ED.
THE rapid molecular testing PLATFORM THAT GIVES YOU A CHOICE
The ID NOW™ platform lets you choose a specific assay based on patient presentation, circulating prevalence, and seasonality of SARS-COV-2, Influenza A & B, RSV, and Strep A. Selecting the right assay at the right time enables you to optimise positive predictive value, reduce unnecessary testing, and enhance diagnostic stewardship.
WHY CONSIDER DISEASE SEASONALITY AND PREVALENCE?
Because they impact the positive predictive value (PPV) of the assay—the likelihood that a person with a positive test result actually has the disease being tested.
Imagine testing 100 patients for the flu using a hypothetical diagnostic test with a sensitivity of 100% and a specificity of 97%.
During peak flu season, there will be many positive test results and the PPV will be high.
In non-peak season there will be fewer positive test results and the PPV will be much
lower—in fact, as many as half of all positive results are likely to be false positive.
Learn more about diagnostic stewardship and positive
predictive value.
PPV During
High Prevalence
Low Prevalence
*76% of emergency ED clinicians spend less than 16 minutes with a patient.6
†Within 7 days of symptom onset. ††Results are specific to direct swab.
ED: emergency department; pED: pediatric emergency department; EMR: electronic medical record; POC: point of care; PPV: positive predictive value; RT-PCR: reverse transcription polymerase chain reaction; UTM: universal transport medium; VTM: viral transport medium.
- ID NOW™ COVID-19 2.0 Product Insert.
- ID NOW™ Influenza A & B 2 Product Insert.
- ID NOW™ RSV Package Insert. Abbott Diagnostics Scarborough, Inc.; 2020. https://imgcdn.mckesson.com/CumulusWeb/Click_and_learn/ID_Now_RSV_Package_Insert.pdf.
- ID NOW™ Strep A 2 Product Insert.
- Abbott. Data on File. ID NOW™ TM Strep A 2 clinical assertion data.
- Grisham S. Medscape Emergency Medicine Physician—Physician Compensation Report 2017. Accessed December 18, 2024. https://www.medscape.com/slideshow/compensation-2017-emergency-medicine-6008568.
